Prilosec OTC boosts P&G outlook
This article was originally published in The Tan Sheet
Earnings per share for third quarter and fiscal year expected to exceed estimates by $0.01 to $0.02 due to strong organic volume growth and sales performance of Prilosec OTC and other products including Crest Whitening Expressions, firm announces March 9. P&G also announced board approval of a 2-for-1 stock split on May 21, 2004. Separately, board increases annual rate of common stock and Series A ESOP Convertible Preferred Stock dividend from $1.82 to $2.00 per share, the second dividend increase this fiscal year...
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.